...
首页> 外文期刊>Endocrine Pathology >The Relationship of the BRAFV600E Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomas
【24h】

The Relationship of the BRAFV600E Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomas

机译:乳头状甲状腺癌BRAFV600E 突变与已建立的预后因素的关系

获取原文
获取原文并翻译 | 示例

摘要

It has been shown that BRAFV600E mutation in papillary thyroid carcinomas (PTC) is associated both with pathogenesis and poor prognosis. In this study, we aimed to investigate the relationship of the BRAFV600E mutation and the established prognostic factors in a cohort of Turkish patients with PTC. Forty-six cases of papillary thyroid carcinoma have been evaluated for the presence of BRAFV600E mutation. BRAFV600E has been examined by restriction fragment length polymorphism. BRAFV600E mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis. We have found that BRAFV600E mutation was present in the majority of our cases (40/46). Considering the stage of the disease, five of the negative cases were in stage 1 while the remaining one was in stage 2. Only one BRAFV600E negative case has shown extrathyroidal extension and lymph node metastasis. All four patients with distant metastasis had BRAFV600E mutation. Statistical analyses revealed that there are no significant relationship between the BRAFV600E mutation and the established prognostic factors. We found a relatively higher BRAFV600E mutation rate in classical type PTC than in other similar studies. We think that the limited number of our cases may either weaken or mask some potentially important relationship between BRAFV600E mutation and the established prognostic factors.
机译:研究表明,甲状腺乳头状癌(PTC)的BRAFV600E 突变与发病机制和预后不良有关。在这项研究中,我们旨在研究BRAFV600E 突变与土耳其PTC患者队列中已建立的预后因素的关系。对46例甲状腺乳头状癌的BRAFV600E 突变进行了评估。已通过限制性片段长度多态性检查了BRAFV600E 。已经将BRAFV600E 突变状态与众所周知的组织病理学和临床预后参数进行了比较,例如甲状腺囊的浸润,甲状腺外延伸,淋巴结的存在和/或远处转移。我们发现在我们的大多数病例中都存在BRAFV600E 突变(40/46)。考虑到该疾病的阶段,在第一阶段中有五例阴性病例,而在第二阶段中是另一例。只有一例BRAFV600E 阴性病例显示出甲状腺外扩张和淋巴结转移。 4例远处转移患者均发生BRAFV600E 突变。统计分析表明,BRAFV600E 突变与已建立的预后因素之间无显着关系。我们发现经典型PTC中的BRAFV600E 突变率比其他类似研究中更高。我们认为有限的病例数可能会削弱或掩盖BRAFV600E 突变与已建立的预后因素之间的某些潜在重要关系。

著录项

  • 来源
    《Endocrine Pathology 》 |2012年第3期| p.135-140| 共6页
  • 作者单位

    Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

    Kaman Vocational School, Ahi Evran University, Kırıkkale, Turkey;

    Department of Nuclear Medicine, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

    Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

    Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

    Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

    Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Papillary thyroid carcinoma; BRAFV600E; Prognosis; Diagnosis;

    机译:甲状腺乳头状癌;BRAFV600E;预后;诊断;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号